J0172 aducanumab-avwa HCPCS Reimbursement

HCPCS Level II code J0172 identifies a 2 mg unit of aducanumab-avwa injection, a monoclonal antibody therapy used in clinical management of Alzheimer’s disease pathology. Nationally, accurate coding for high-cost biologic infusions like aducanumab-avwa is important for billing consistency, payer coverage determinations, and reporting of utilization and spending for specialty therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used in practice, the typical service settings where the drug is administered, and the elements that influence billing and reimbursement for unit-based HCPCS codes. The publication outlines benchmark considerations for payers, common modifier usage where applicable, and the clinical context surrounding aducanumab-avwa administration.

This report also summarizes expected documentation elements tied to infusion/injection services and highlights where policy updates or coverage criteria from major payers could affect coding and payment. Data not available in the input is noted where specific payer coverage policies, ICD-10 pairings, and related codes would ordinarily be detailed.

Billing Code Overview

HCPCS Level II code J0172 represents injection, aducanumab-avwa, 2 mg. This code denotes the administration of a 2 mg unit of aducanumab-avwa, a monoclonal antibody therapy indicated for treatment related to Alzheimer’s disease pathology.

Service Type: Pharmacologic infusion/injection therapy

Typical Site of Service: Hospital outpatient department, infusion center, or ambulatory clinic

Data not available in the input.

Clinical Context

A typical patient is an older adult diagnosed with early symptomatic Alzheimer disease or mild cognitive impairment due to Alzheimer pathology who is being treated in a neurology infusion center. The patient presents for a scheduled intravenous infusion of J0172 (aducanumab-avwa), dosed in 2 mg units per billing increment and administered per the FDA-approved dosing schedule after baseline evaluation. The clinical workflow includes: pre-infusion nursing assessment (vital signs, weight, review of concurrent medications and allergies), verification of the most recent brain MRI for amyloid-related imaging abnormalities (ARIA), informed consent documentation specific to aducanumab-avwa risks and benefits, pharmacy preparation and verification of dose, administration by an infusion nurse under neurologist or infusion center physician oversight, monitoring during and for a period after infusion for infusion reactions or neurologic changes, and documentation of dose, lot number, and any adverse events. Follow-up visits include periodic cognitive assessments and interval MRIs per prescribing and payer requirements.

Coding Specifications

Modifier	Description	When to Use
`11`	Office or other outpatient services, normal; used to indicate the service is performed by the physician as usual	When the supervising physician performs or personally provides the infusion service elements

Taxonomy Code	Specialty	Notes
`207RH0000X`	Neurology	Neurologists prescribe and oversee aducanumab-avwa therapy
`332B00000X`	Infusion Therapy	Infusion specialists and centers that administer biologic infusions
`207K00000X`	Geriatric Medicine	Geriatricians manage cognitive disorders and coordinate infusion therapy
`2085R0206X`	Internal Medicine - Subspecialty (Behavioral Neurology)	Specialists focused on dementia care and infusion oversight
`363A00000X`	Nursing (Infusion/Infusion Therapy Nurse)	Nursing professionals who deliver and monitor the infusion

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G30.0`	Alzheimer disease with early onset	Indicates Alzheimer disease for which aducanumab-avwa may be considered in early symptomatic patients
`G30.1`	Alzheimer disease with late onset	Common diagnostic category for patients undergoing disease-modifying therapy assessment
`G30.9`	Alzheimer disease, unspecified	Used when specific onset timing is not documented but therapy applies to Alzheimer pathology
`F02.8`	Dementia in other diseases classified elsewhere	May apply when Alzheimer pathology coexists with other neurologic disorders being treated
`G31.84`	Mild cognitive impairment, so stated	Often the indication for assessment prior to initiation of disease-modifying therapy such as aducanumab-avwa

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used to bill the initial infusion encounter administration time when `J0172` is infused as the primary therapeutic agent
`96366`	Intravenous infusion, each additional hour	Used for extended infusion duration beyond the initial hour when clinically necessary for infusion of `J0172`
`96374`	Injection, therapeutic, prophylactic, or diagnostic; intravenous push, single or initial substance/drug	Applicable if a bolus medication (e.g., premedication) is administered as an IV push during the infusion visit
`96376`	Each additional sequential IV push of a new substance/drug	For additional IV push medications given during the same encounter (e.g., antiemetic or antihistamine)
`77053`	Magnetic resonance imaging, brain, without and with contrast when performed for treatment monitoring	Ordered before or during the treatment course to monitor for ARIA and treatment safety in patients receiving `J0172`

OpenPayer

Summary & Overview

HCPCS J0172: Injection, aducanumab-avwa, 2 mg